MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
TESTING,89162				W2935057
Ordering Phys		**DOB**		
Client Order # W2935057	**Account Information** C7999998-STUSTEST 200 FIRST STREET SW ROCHESTER, MN 55901 (507)266-5730	**Report Notes**		
Collected 10/15/2009 06:00				
Printed 10/16/2009 15:13				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Circulating Tumor Cells, Colorectal			REPORTED 10/15/2009 13:19		
Specimen		Whole Blood			MCR
Specimen ID		67511			MCR
Order Date		14 OCT 2009 09:43			MCR
Reason For Referral					MCR
Assess for Circulating Tumor Cells					
Method					MCR
CellSearch (TM) System					
Result					MCR
Negative, 0 circulating tumor cells/7.5 mL of blood.					
Interpretation					MCR
The results of this test are negative (<3 circulating tumor cells/7.5 mL of blood). In patients with metastatic colon cancer, negative results are predictive of longer progression-free survival (PFS). In one prospective multicenter study, circulating tumor cells (CTCs) were enumerated in the peripheral blood of 430 patients with metastatic colorectal cancer at baseline and after starting first-, second-, or third-line therapy. CTCs were measured using an immunomagnetic separation technique. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of three or more or less than three CTCs/7.5 mL, respectively. Patients with unfavorable compared with favorable baseline CTCs had shorter median progression-free survival (PFS; 4.5 v 7.9 months; P = .0002) and overall survival (OS; 9.4 v 18.5 months; P < .0001). Differences persisted at 1 to 2, 3 to 5, 6 to 12, and 13 to 20 weeks after therapy. Conversion of baseline unfavorable CTCs to favorable at 3 to 5 weeks was associated with significantly longer PFS and OS compared with patients with unfavorable CTCs at both time points (PFS, 6.2 v 1.6 months; P = .02; OS, 11.0 v 3.7 months; P = .0002). Among non-progressing patients, favorable compared with unfavorable CTCs within 1 month of imaging was associated with longer survival (18.8 v 7.1 months; P < .0001). Baseline and follow-up CTC levels remained strong predictors of PFS and OS after adjustment for clinically significant factors (Cohen SJ et al., J Clin Oncol. 26:3213-21, 2008.)					
Reviewed By					MCR
Amy Catherine Clayton MD					
Release Date		14 Oct 2009 16:20			MCR

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
TESTING,89162				W2935057
Ordering Phys		**DOB**		
Client Order # W2935057	**Account Information** C7999998-STUSTEST 200 FIRST STREET SW ROCHESTER, MN 55901 (507)266-5730	**Report Notes**		
Collected 10/15/2009 06:00				
Printed 10/16/2009 15:13				

Test	Flag	Results	Unit	Reference Value	Perform Site*

>> Accession W2935057 - Continued From Previous Page <<
>> Do Not Discard <<

* Performing Site:

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First St SW Rochester, MN 55905	Lab Director:

* Report times for Mayo performed tests are CST/CDT